Press "Enter" to skip to content

Generic Antidepressants may reduce the Severity of Covid-19

Researchers announced Wednesday that a low-cost, generically accessible Antidepressants could cut the chance of severe Covid-19 disease by about a third in those at high risk. In a study of roughly 1,500 patients in Brazil, it was discovered that those who took the medicine fluvoxamine were less likely to develop severe disease and require hospitalization. The medicine is a selective serotonin reuptake inhibitor (SSRI) commonly used to treat obsessive-compulsive disorder (OCD) and depression. It is offered under the trade name Luvox.

But, according to Dr. Angela Reiersen, an associate professor of psychiatry at Washington University in St. Louis who worked on the study, which was published in The Lancet Global Health, it can influence inflammation. Reierson and colleagues provided Covid-19 100 mg fluvoxamine twice a day for ten days to 741 volunteers and a placebo to 756 others. Patients who received fluvoxamine required treatment in an ER or hospital room 79 percent of the time, compared to roughly 16 percent of those who received placebos.

There was a 5% reduction in absolute risk and a 32% reduction in relative risk. More research is needed to evaluate if the medicine could be added to coronavirus treatments, but inexpensive. “Even in well-resourced settings, a 10-day course of fluvoxamine costs around $4,” the researchers stated. Although the medicine isn’t a cure, it could be beneficial in keeping patients out of the hospital.

Prozac, or fluoxetine, is a related medicine that is equally inexpensive and widely available, and the researchers believe it should be investigated to see whether it can assist. However, they acknowledged that the study wasn’t flawless. It was carried out in Brazil, and the patients were admitted to the hospital at a higher rate than Covid-19 patients in other trials.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *